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The malaria-causing parasite Plasmodium falciparum is
responsible for over 200 million infections and 400,000 deaths
per year. At multiple stages during its complex life cycle,
P. falciparum expresses several essential proteins tethered to its
surface by glycosylphosphatidylinositol (GPI) anchors, which are
critical for biological processes such as parasite egress and
reinvasion of host red blood cells. Targeting this pathway therapeutically has the potential to broadly impact parasite development across several life stages. Here, we characterize an
upstream component of parasite GPI anchor biosynthesis, the
putative phosphomannomutase (PMM) (EC 5.4.2.8), HAD5
(PF3D7_1017400). We conﬁrmed the PMM and phosphoglucomutase activities of puriﬁed recombinant HAD5 by developing novel linked enzyme biochemical assays. By regulating the
expression of HAD5 in transgenic parasites with a TetR-DOZIinducible knockdown system, we demonstrated that HAD5 is
required for malaria parasite egress and erythrocyte reinvasion,
and we assessed the role of HAD5 in GPI anchor synthesis by
autoradiography of radiolabeled glucosamine and thin layer
chromatography. Finally, we determined the three-dimensional
X-ray crystal structure of HAD5 and identiﬁed a substrate analog
that speciﬁcally inhibits HAD5 compared to orthologous human
PMMs in a time-dependent manner. These ﬁndings demonstrate
that the GPI anchor biosynthesis pathway is exceptionally sensitive to inhibition in parasites and that HAD5 has potential as a
speciﬁc, multistage antimalarial target.

Malaria remains an enormous global health burden for most
of the world, resulting in over 200 million infections and
400,000 deaths every year, the majority of which are in children under the age of 5 years (https://www.who.int/
publications/i/item/9789240015791, accessed May 14, 2021).
One of the primary barriers to effective malaria treatment and
control is the emergence of resistance to all approved antimalarial chemotherapeutics (1, 2), prompting an urgent call for
the development of new therapies and the identiﬁcation of

novel drug targets. Malaria is caused by apicomplexan parasites of the genus Plasmodium, primarily the species Plasmodium falciparum. P. falciparum has a complex life cycle, in
which parasites develop in a mosquito host, are deposited into
a human during a mosquito blood meal, and migrate to the
liver where they infect hepatocytes. Parasites are released from
the liver into the bloodstream and begin an asexual cycle of
replication within red blood cells (RBCs), occasionally
branching off into sexual-stage gametocytes that can be taken
up by mosquitoes to start the cycle anew (3).
This complex, multihost life cycle has stymied efforts to
develop therapeutics and vaccines to eradicate this disease, as
it has been difﬁcult to identify effective vaccine and therapeutic
targets that span multiple life stages. In recent years, the push
for new therapeutics and vaccines has focused on a strategy of
developing transmission-blocking vaccines and therapies,
which impair the development or viability of gametocytes or
target the mosquito vector itself, thus preventing vector-borne
transmission (4–6). Our goal is therefore to identify novel
targets for antimalarial therapeutics that are not only essential
for intraerythrocytic growth of the parasite but also essential
for sexual-stage and/or mosquito-stage parasites, indicating
their potential in transmission-blocking strategies.
Malaria parasites are highly metabolically active (7, 8), and
several known antimalarials target unique and essential metabolic processes in the parasites (9–13). Metabolic enzymes have
great potential for chemical inhibition, as substrate analogs can
be rationally designed and developed as potential inhibitors,
making these enzymes well suited as “druggable” targets (14).
We therefore sought a metabolic enzyme that is expressed and
essential during multiple life stages of P. falciparum. These
constraints narrowed our search to the upstream steps of glycosylphosphatidylinositol (GPI) anchor synthesis.
GPI anchors are an essential component of all life stages of
P. falciparum. In intraerythrocytic parasites, these glycolipid
anchors tether several essential proteins to the parasite plasma
membrane prior to RBC egress and reinvasion (15). Most
abundant among these GPI-anchored proteins (GPI-APs) is
merozoite surface protein 1 (MSP1) (15–17). Proper MSP1
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localization and processing are necessary for parasites to egress
from the erythrocyte, and mature MSP1 anchored to the
surface of free merozoites facilitates the binding and invasion
of new RBCs. In the absence of the GPI-anchoring C terminus
of MSP1, parasites are defective in their ability to egress (18),
and antibodies developed against MSP1 prevent merozoite
reinvasion (19). Several other GPI-APs are also involved in
parasite egress and invasion, including other MSPs and
rhoptry-associated membrane antigen (15, 17, 20). GPI-APs
are also expressed in other life stages of P. falciparum.
Gamete-stage and ookinete-stage GPI-APs include Pfs25 and
Pfs230, which are considered as possible vaccine candidates
(21–24), while circumsporozoite protein, the critical antigen of
the RTS,S and R21 vaccines, is an essential GPI-AP of the
sporozoite stages (25–29). Thus, it is clear that successful
targeting of GPI anchor biosynthesis would not only effectively
treat symptomatic blood-stage infection but may also block
transmission of the parasites at multiple stages.
One enzyme of the GPI anchor biosynthesis pathway that is
yet to be characterized in P. falciparum is the putative phosphomannomutase (PMM), HAD5 (PMM; PF3D7_1017400).
PMMs are responsible for the conversion of mannose 6phosphate (M6P) to mannose 1-phosphate (M1P), the precursor to GDP-mannose. GDP-mannose is then converted to
dolichol-p-mannose, which is the building block for incorporating mannose into glycolipids. In asexual P. falciparum, the
dominant mannosylated glycolipids are GPI anchors (30), as
N-glycans in these parasites only contain N-acetyl glucosamine
(31–33); therefore, targeting of mannose metabolism is predicted to speciﬁcally inhibit GPI anchor synthesis. HAD5 is
also predicted to be essential (34), and transcriptomic studies
show its expression during the blood stage (35, 36) and sexual
stages (37), making it a potential multistage antimalarial drug
target. In this study, we characterize the putative PMM of
P. falciparum, HAD5, demonstrating its essentiality for parasite growth and its potential for speciﬁc targeting by future
antimalarial therapies.

Results
HAD5 is a PMM
HAD5 (PF3D7_1017400) has been annotated as a putative
PMM through homology to other known PMMs. PMMs are
responsible for interconverting M6P and M1P to generate
M1P for downstream glycolipid production, most notably GPI
anchors in P. falciparum (Fig. 1A) (38–40). To determine the
biochemical function of HAD5, we puriﬁed recombinant
HAD5 (Fig. 1B) and examined its hexose phosphate mutase
activities (Figs. 1C and S1). We found that HAD5 was active in
the PMM assay (0.56 ± 0.48 μmol/min/mg), with even more
robust activity (7.67 ± 0.06 μmol/min/mg) upon addition of
the known cofactor glucose-1,6-bisphosphate (G-1,6-P) (40),
which is comparable to the speciﬁc activity of other PMMs (41,
42). Although turnover number (kcat) was much lower in our
assays than that of other assays for PMM activity (43, 44), it
should be noted that the majority of the published work on
PMM activity has investigated the reverse PMM reaction,
converting M1P to M6P, at 37  C. It is therefore difﬁcult to
directly compare the reaction rate of our forward reaction
assay at room temperature. Furthermore, as has been seen for
other PMMs (42, 45), HAD5 exhibits some promiscuity in its
substrate preference, as it also displays phosphoglucomutase
(PGM) activity at 0.31 ± 0.03 μmol/min/mg. Comparison of
the catalytic efﬁciencies of HAD5 toward phosphomannose
and phosphoglucose suggests that PMM activity is the dominant enzymatic function of HAD5, with a roughly 4-fold
higher catalytic efﬁciency (kcat/Km) compared to its PGM activity (Table 1). HAD5 activity against other phosphosugars, or
using other bisphosphate activators, was not assessed.
HAD5 is essential for intraerythrocytic parasite growth
To assess the essentiality of HAD5 in intraerythrocytic
parasite stages, we used a previously described conditional
knockdown system in cultured asexual P. falciparum (46, 47)
(Fig. 2A). We placed a Tet repressor-binding aptamer array at

Figure 1. HAD5 is a bifunctional phosphomannomutase/phosphoglucomutase. A, schematic of phosphomannomutases’ role in metabolism. Phosphomannomutases like HAD5 interconvert mannose 6-phosphate and mannose 1-phosphate, providing the latter for downstream glycolipid production
and synthesis of GPI anchors in P. falciparum. B, SDS-PAGE gel of recombinant WT HAD5 and a catalytically inactive mutant (D11A). C, displayed are the
mean ± SEM of HAD5 activity across three independent trials, with D11A activity subtracted as background. p-values were determined using an ordinary
two-way ANOVA (Tukey’s test for multiple comparisons, α = 0.05). ****p < 0.0001, ns = not signiﬁcant. G-1,6-P, glucose-1,6-bisphosphate; GPI, glycosylphosphatidylinositol; PGM, phosphoglucomutase assay; PMM, phosphomannomutase assay.
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Table 1
Phosphomannomutase and phosphoglucomutase activity of HAD5
Enzyme assay
PMM
PGM

kcat (s−1)
−4

−5

1.7 × 10 ± 1.9 × 10
7.8 × 10−6 ± 1.2 × 10−6

Km (μM)

kcat/Km (M−1 s−1)

32 ± 3.6
5.2 ± 1.4

5.4
1.5

Displayed are the mean ± SEM of three independent trials for the kinetic parameters of
HAD5 converting M6P to M1P (PMM) or G1P to G6P (PGM).
Abbreviations: G1P, glucose 1-phosphate; G6P, glucose 6-phosphate; PGM,
phosphoglucomutase; PMM, phosphomannomutase.

the 30 -end and 50 -end of the endogenous HAD5 locus by
CRISPR/Cas9-mediated integration. In parasite integrants, the
presence of anhydrotetracycline (aTc) promotes HAD5
translation, while washing out aTc leads to inhibition of
translation, and we term this conditional knockdown strain
“HAD5KD”. Immunoblotting conﬁrms substantial reduction in
cellular abundance of HAD5 in the absence of aTc (Fig. 2B). In
HAD5KD parasites, 0 nM aTc conditions led to an absence of
growth, whereas addition of aTc promoted growth in a dosedependent manner (Fig. 2C), indicating that HAD5 is essential for asexual growth of P. falciparum.
Because phosphosugar mutases often utilize more than one
substrate, we examined whether the PMM activity of HAD5
was responsible for its essential function in asexual parasites.
Attempts to chemically rescue parasite growth with hexose
phosphates such as M6P and M1P were unsuccessful

(Fig. S2A), as was expected because of the impermeability of
the erythrocyte and parasite membranes to such highly
charged compounds. However, we found that simple chemical
supplementation of the media with D-mannose was sufﬁcient
to rescue growth when HAD5 expression is reduced. This
indicates that the primary mechanism of death in these parasites is due to defects in mannose metabolism (Figs. 2D and
S2B). Notably, while artiﬁcially elevated concentrations of
D-mannose completely rescued parasite growth, a physiologically relevant concentration of 50 μM [equivalent to that of
human serum (48)] did not provide a statistically signiﬁcant
rescue of parasite growth.
HAD5 is required for parasite egress and invasion
GPI anchors, which contain mannose (15, 17, 30), are
required for egress of the malaria parasite from the infected
host cell, as well as reinvasion of merozoites (47, 49–56).
Because of its essential role in mannose metabolism, we hypothesized that HAD5 may be required for efﬁcient egress and
invasion. To evaluate this possibility, we washed out aTc at the
beginning of the life cycle in synchronized parasites. Parasites
grown in −aTc conditions over the course of one life cycle
developed morphologically normally through the majority of
life cycle stages, including the development of multinucleated
schizonts. While +aTc conditions allowed parasites to continue

Figure 2. HAD5 is essential for intraerythrocytic parasite growth. A, schematic of the regulatable knockdown system introduced at the native locus of
PfHAD5 (46, 47). B, Western blot of transgenic HAD5KD parasite lysate ±aTc, using α-HA to detect HAD5 and α-Plasmepsin V (PMV) as a loading control.
Removal of aTc results in successful knockdown of HAD5. Approximate expected protein masses: PMV, 51 kDa; PfHAD5-3xHA, 32 kDa. C, fold change in
parasitemia over time of HAD5KD parasites grown in varying concentrations of aTc. Data represent mean ± SEM of three independent experiments with
technical duplicates. Signiﬁcance was determined by one-way ANOVA with Fisher’s LSD; *p = 0.03; ***p < 0.001. D, fold change in parasitemia of HAD5KD
parasites grown in varying aTc concentrations with D-mannose rescue. Signiﬁcance was determined by ordinary two-way ANOVA with Tukey’s correction
for multiple comparisons. ****p < 0.0001, ns = not signiﬁcant. Data represent mean ± SEM of three independent experiments with technical duplicates. E,
bright-ﬁeld images of Giemsa-stained thin-smear synchronized parasites over time. aTc, anhydrotetracycline; HPI, hours postinvasion.
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into the next life cycle and form newly reinvaded “ring”-stage
parasites, −aTc parasites were arrested in late schizogony
(Fig. 2E), which suggests a defect in parasite egress when HAD5
expression is knocked down. Notably, when HAD5 expression
is reduced, parasites retain normal mature schizont architecture by transmission electron microscopy, indicating that
neither gross developmental defects nor structural aberrations
prevent parasites from egressing (Fig. S3).
To examine whether HAD5 is required for invasion, as well
as egress, we examined the reinvasion capacity of HAD5KD
parasites. Segmented schizont-enriched cultures of
HAD5KD ±aTc were mechanically lysed, and the freed merozoites were allowed to reinvade fresh RBCs. Under these
conditions, knockdown parasites were unable to reinvade new
host cells (Fig. S4). Thus, the knockdown of HAD5 confers
defects to parasite biology that prevent both egress and reinvasion of the parasites.
HAD5 knockdown disrupts GPI anchor synthesis
Mannose metabolism is linked to parasite egress through
biosynthesis of GPI anchors (57). In P. falciparum, GPI anchors
are synthesized through addition of one glucosamine (GlcN) and
3 to 4 mannose residues to a phosphatidylinositol backbone.
These mannose residues are derived from the product of PMM,
M1P, which is converted to GDP-mannose and subsequently to
dolichol-phosphate mannose, the direct mannose donor to GPI
anchors (Fig. 3A) (58). Several GPI-APs contribute to egress and
invasion of parasites (15, 18, 20). We therefore hypothesized that
reduced HAD5 expression leads to loss of PMM activity and
causes parasite death by disruption of GPI anchor biosynthesis.
To directly evaluate the effect of HAD5 knockdown on GPI
anchor biosynthesis, we labeled mid- to late-trophozoite parasites with [3H]-GlcN and extracted GPI precursors as previously
described (17, 57, 59, 60). HAD5KD parasites grown in +aTc
conditions had the expected repertoire of GPI anchor precursors
(Fig. 3, B and C). A variety of precursors are observed, with
earlier, less polar species (with fewer mannose groups) migrating
further than more polar, highly mannosylated species. When
HAD5 expression is reduced, there is a relative accumulation of
the earlier precursors, as well as a reduced production of fully
mature, highly mannosylated precursors (Fig. 3B), indicating a
defect in GPI anchor biosynthesis. In particular, there was a
signiﬁcant reduction of the highly polar band 9 and signiﬁcant
buildup of less polar band 4 when HAD5 expression was reduced
(Fig. 3C). Intriguingly, despite the substantial knockdown of
HAD5 and the complete loss of growth in these parasites, the
abundance of many mannosylated precursors is unchanged and
highly mannosylated GPI precursors are still observed, suggesting that this biosynthetic pathway is not completely ablated.
To conﬁrm the role of HAD5 in GPI biosynthesis, we
deployed two established chemical tools, mannosamine
(ManN) and GlcN, which impair the growth of P. falciparum
through inhibition of GPI anchor biosynthesis (61, 62). We
expected that if HAD5 knockdown disrupts GPI anchor
biosynthesis, parasites should be hypersensitized to ManN and
GlcN treatment. Indeed, when the expression of HAD5 is
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reduced with an intermediate concentration of aTc (3 nM)
that still permits modest asexual growth, knockdown parasites
yielded a marked shift in EC50 (Fig. 3, D and E). These results
further implicate HAD5 in the production of GPI anchors in
P. falciparum.
HAD5-dependent GPI anchor synthesis enables proper
anchoring of MSP1
Reduced GPI anchor biosynthesis in malaria parasites is expected to impact the localization and function of a number of
essential GPI-anchored parasite proteins. While several GPIAPs have been characterized in P. falciparum intraerythrocytic
stages, the most abundant is MSP1 (15, 16). MSP1 must be targeted and anchored through GPIs and proteolytically processed
for schizont-stage parasites to egress from the erythrocyte, and
the MSP1 complex is also critical for binding and reinvading new
RBCs (18, 63). For this reason, we investigated whether HAD5dependent GPI anchor synthesis is required for localization
and anchoring of MSP1. We expected that, when the pathway is
intact, MSP1 is successfully anchored to the parasite plasma
membrane. In contrast, when HAD5 expression is knocked
down, GPI anchors will fail to fully incorporate mannose, and
GPI-APs, including MSP1, will remain untethered to the membrane (Fig. 3A). To evaluate this effect, we used immunoﬂuorescence to detect the localization of MSP1. When schizonts
grown in ±aTc conditions were mechanically lysed and the
resultant merozoites were imaged, there was a modest but signiﬁcant decrease in MSP1 signal surrounding the daughter
merozoites when HAD5 expression is reduced (Fig. 4, A and B),
indicating that MSP1 membrane attachment is diminished,
causing it to diffuse away from the cell.
To independently conﬁrm this ﬁnding, we partitioned lysate
from early schizont-stage parasites into membranous and
soluble fractions (64). Whole lysate and fractions were assessed
by immunoblotting for MSP1, and the relative proportion of
MSP1 in the membrane fraction compared to lysate was
calculated. In +aTc conditions, a large proportion of MSP1
separates with the detergent-enriched phase, with some fulllength MSP1 in the soluble phase. Upon HAD5 knockdown,
there was a subtle reduction in the proportion of cellular
MSP1 bound to the membrane (Fig. S5). This difference did
not reach signiﬁcance; however, substantial biological variability in MSP1 expression is present within merozoite populations, as indicated in Figure 4B, and post hoc power analysis
of these data indicates that we were underpowered to observe
a signiﬁcant difference (power = 0.290) (65). Together with our
analysis of GPI anchor biosynthesis in these parasites (Fig. 3),
these data conﬁrm some functional preservation of GPI
biosynthesis when HAD5 expression is reduced.
Disruption of mannose metabolism by HAD5 knockdown does
not affect fosmidomycin sensitivity in parasites
HAD5 and other PMMs are part of the haloacid dehalogenase (HAD) superfamily of proteins (Interpro: IPR023214), a
ubiquitous family of enzymes that primarily conduct phosphatase and phosphotransferase reactions (66). HAD5 is a
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Figure 3. Knockdown of HAD5 disrupts GPI anchor biosynthesis. A, model of the predicted effect that knocking down HAD5 will have on GPI anchor
precursor synthesis and subsequent anchoring of GPI-APs. B, representative autoradiography ﬁlm of GPI anchor precursors from [3H]GlcN-labeled parasites.
Bands toward the top migrated farthest on a silica TLC plate, indicating they are less polar and less mannosylated. C, the radiographic signal was quantiﬁed
and is represented as proportions of total signal. Band numbers indicate the corresponding band from A. Shown are the mean and SEM of three independent experiments, analyzed by ordinary two-way ANOVA with Fisher’s LSD test. *p = 0.038, **p = 0.008. D and E, dose–response curve of parasite growth
in the presence of GlcN (D) or mannosamine (ManN; E). Data represent the means and SEM of three independent experiments with technical replicates. Aps,
anchored proteins; E, ethanolamine; GlcN, glucosamine; GPI, glycosylphosphatidylinositol; Ins, inositol; M, mannose; M1P, mannose 1-phosphate; M6P,
mannose 6-phosphate.

member of subfamily IIB (IPR006379) of the HAD superfamily
and has substantial sequence homology to other P. falciparum
HAD proteins in this subfamily (HAD1 and HAD2) and the
related subfamily IIA (IPR006357) protein, phosphoglycolate
phosphatase (67). One notable commonality between these
subfamily II P. falciparum HAD proteins is their effect on the
parasite’s sensitivity to the antimalarial fosmidomycin (FSM),
which is a well-validated inhibitor of the apicoplast methylerythritol phosphate pathway of isoprenoid biosynthesis (9).
Mutations in either HAD1 (68) or HAD2 (69) render parasites
resistant to FSM, and phosphoglycolate phosphatase knockout
parasites are hypersensitive to FSM (70). To examine whether

HAD5 also plays a role in FSM susceptibility, we assessed the
FSM dose–response of parasites grown in saturating or intermediate aTc conditions. Unlike its close homologs, HAD5
knockdown had no effect on the FSM EC50 of parasites
(Fig. S6).
HAD5 is distinct from human PMMs and can be speciﬁcally
inhibited
Previous studies have investigated egress and invasion as a
promising target for antimalarial drug discovery, suggesting
that HAD5 may likewise be of interest for antimalarial drug
J. Biol. Chem. (2022) 298(2) 101550
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Figure 4. Knockdown of HAD5 diminishes membrane anchoring of the egress and invasion protein MSP1. A, representative immunoﬂuorescent
images of mechanically freed merozoites that were grown in ±aTc conditions and schizont enriched by E64 treatment. B, quantiﬁcation of MSP1 signal from
A. Data points represent three independent experiments, each with >25 observed merozoites, removing those under a threshold of 10,000 RFU. Bar graphs
represent the mean ± SEM of all data points. Statistics were performed by Mann–Whitney test. **p = 0.008. aTc, anhydrotetracycline; E64, epoxysuccinyl-Lleucylamido(4-guanidino)butane; MSP1, merozoite surface protein 1.

discovery (47, 49–52); however, PMMs are found widely
throughout nature, including two genes in the human genome,
HsPMM1 and HsPMM2 (71, 72). We therefore evaluated the
potential for selective inhibition of P. falciparum HAD5 over
human PMM1 and PMM2 (Fig. S7A). Previous work has
successfully demonstrated the use of substituted ketoheptoses
and other phosphosugar analogs as inhibitors of microbial
PMMs (73, 74), which we sought to replicate with HAD5.
Using a panel of 11 phosphosugar analogs (Fig. S8A), we
screened each compound for its ability to inhibit recombinant
HAD5, PMM1, and PMM2. The majority of the compounds
had negligible inhibition against all three enzymes (Fig. S8).
Compound D9, however, inhibits puriﬁed recombinant HAD5
with a half-maximal inhibitory concentration of 79 ± 2.6 μM,
severalfold more potently than the inhibition of either PMM1
or PMM2 (Fig. 5A). Moreover, we ﬁnd dramatic timedependent effects on the ability of D9 to inhibit HAD5, as
preincubating HAD5 with D9 prior to assaying activity
substantially increased D9 potency, such that a 60-min
preincubation yielded HAD5 activity of only 4.5% of a
vehicle-treated control (Fig. 5B). This effect was not seen for
HsPMM1, demonstrating that the potential to speciﬁcally
inhibit HAD5 may be even greater under ideal binding conditions. As expected, given its poor drug-like characteristics
(and likely inadequate cellular permeability), compound D9
did not impair the growth of asexual P. falciparum at concentrations up to 100 μM (Fig. S9A). The selective inhibition of
HAD5 by D9 is an important proof-of-concept that distinct
structural features of HAD5 may be harnessed for parasitespeciﬁc inhibitor development.
To uncover the structural basis for HAD5-speciﬁc inhibition, we solved the X-ray crystal structure of HAD5 to 3.5 Å
resolution. Data collection and reﬁnement statistics are summarized in Table 2. Like other known PMMs and members of
the HAD superfamily (66, 75), HAD5 comprises two domains
with an overall fold similar to that of HsPMM1 (Fig. 5C). There
were no large structural differences in the overall threedimensional folds of the human and parasite enzymes.
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However, the effectiveness of compound D9 in inhibiting
HAD5 compared to human PMMs (Fig. 5A) suggests that the
inhibitor binding sites have differences that may account for
this. Compounds D1 to D11 were synthesized as substrate
mimetics that inhibit enzymes at the substrate binding pocket,
which is supported by cocrystal structures with structurally
related inhibitors bound to the active site of related proteins
(74). We therefore hypothesized that D9 inhibits HAD5 at the
active site. Although many active site features between the
Plasmodium and human enzymes are conserved, an active site
loop contains signiﬁcant sequence variations (Fig. S9B). This
loop in HAD5 contains Met173, Gln176, and Ile179, whereas
the corresponding residues in PMM1 are Arg183, Met186, and
Phe189 (Fig. S9B). To develop a model for how compound D9
may interact with HAD5, we computationally docked the
ligand into the active site of the HAD5 X-ray crystal structure.
The resulting position of D9 in the HAD5 active site is similar
to the crystallographically determined binding mode of
mannose-1-phosphate in the X-ray structure of human PMM1
(76). The docking solution orients the hydroxyaminomethyl
group of compound D9 in proximity to the sidechains of
residues in the variable active site loop (Fig. S9B). Furthermore, comparison of D9 to similar but less potent compounds
used for HAD5 inhibitor screening, D7 and D11, indicates that
the hydroxyaminomethyl group is a key determinant of HAD5
inhibition compared to the human PMM (Fig. S7). Although
the combination of low resolution of the HAD5 crystal
structure and computational docking precludes more detailed
analysis, the resulting model suggests that interactions between the hydroxyaminomethyl group of D9 and the variable
active site loop likely account for HAD5 selectivity; however,
additional studies are needed to further validate this model.

Discussion
We report here the lethal knockdown and biochemical
characterization of the PMM in P. falciparum, HAD5. Loss of
HAD5 leads to growth arrest in asexually replicating parasites,
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Figure 5. HAD5 is sufﬁciently distinct from human PMMs to be speciﬁcally inhibited. A, dose–response curve of compound D9 against recombinant
PfHAD5, HsPMM1, and HsPMM2. Data represent the mean ± SEM of three independent experiments, each with technical replicates. B, activity of PfHAD5 or
HsPMM1 was assayed after preincubating enzymes for the given time with 416 μM of D9 prior to adding the preincubation to the reaction mix (ﬁnal [D9] =
50 μM). As a control (ctrl), enzymes were incubated with an equal volume of water for 60 min. Statistics were performed with an ordinary two-way ANOVA,
using Dunnett’s test for multiple comparisons. **p = 0.0046, ****p < 0.0001, ns, not signiﬁcant. C, 3.5 Å resolution crystal structure of PfHAD5 (orange)
aligned to HsPMM1 (cyan; PDB 2FUC) with Mg2+ ions (purple). Indicated are the cap and core domains typical of HAD enzymes. HAD, haloacid dehalogenase;
PMM, phosphomannomutase.

marked by defects in egress and reinvasion. This growth defect
can be rescued by media supplementation with D-mannose,
indicating that disruption of mannose metabolism is the primary mechanism of death in HAD5KD parasites; however, a
physiologically relevant concentration of 50 μM D-mannose is
unable to signiﬁcantly rescue growth, bolstering the case for
this pathway as a therapeutic target. We further report the
speciﬁc inhibition of HAD5 enzymatic activity compared to

Table 2
Summary of crystallographic statistics
Crystal
Space group
Cell dimensions
Data collection
Wavelength
Resolution range (highest shell)
Reﬂections (total/unique)
Completeness (highest shell)
<I/σ> (highest shell)
Rsym (highest shell)
Reﬁnement
Rcrys/Rfree
No. of protein atoms
No. of ligand atoms
R.m.s. deviation, bond lengths
R.m.s. deviation, bond angles
Avg. B-factor: protein, ligand
Stereochemistry: favored, allowed, outliers

PfHAD5
P6522
a = b = 161.3. Å, c = 109.7 Å
0.979 Å
40.3–3.50 Å (3.56–3.520 Å)
354,596/11,030
99.9% (100%)
18.5 (2.7)
33.4% (143%)
25.4%/31.0%
3941
2
0.003 Å
0.74
92.7, 59.1 Å2
94.7, 4.5, 0.8%

orthologous human PMMs by the hexose–phosphate analog,
compound D9, highlighting the potential for speciﬁc therapeutics to be developed to HAD5.
While difﬁcult to compare to other published PMM activities, the kcat of HAD5 for its mannose–phosphate substrate is
low. This may be a result of the reaction conditions, as we were
implementing a linked enzyme reaction that assayed the
conversion of M6P to M1P, rather than the more commonly
assayed inverse reaction. We also performed these assays at
room temperature, rather than 37  C. Despite those caveats, it
remains possible that HAD5 is capable of catalyzing more
robust reactions with other phosphosugar substrates or
bisphosphate activators, particularly because we and others
have observed that HAD proteins demonstrate considerable
substrate promiscuity (77, 78). However, the observation that
mannose supplementation rescues HAD5KD parasite growth
supports our hypothesis that the essential activity of HAD5 is
mediated through its impacts on mannose metabolism.
Unexpectedly, despite the dramatic decrease in HAD5
protein levels and the compelling loss of growth upon HAD5
knockdown, GPI anchor synthesis and MSP1 anchoring to
merozoite surfaces are only modestly impacted. It may be that
residual HAD5 activity, below the limit of detection by
immunoblot analysis, is present after knockdown and sufﬁcient for generating detectable GPI precursors and subsequent
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tethering of some GPI-APs. Alternatively, P. falciparum expresses two annotated PGMs (PF3D7_1012500 and
PF3D7_0413500) (79) that could potentially catalyze PMM
activity as well, which would suggest some functional redundancy to HAD5. However, the related apicomplexan organism
Toxoplasma gondii also harbors two PGM isozymes, which
lack PMM activity (80, 81), suggesting that P. falciparum
PGMs also may lack this activity. Residual HAD5 or functional
redundancy by PGMs could also explain our observation that
D-mannose rescues HAD5 knockdown. Intracellular mannose
is likely converted to M6P by hexokinase and thus some PMM
activity would still be required for successful rescue of the GPI
anchor pathway. Regardless of the source of residual GPI
anchoring, the absence of another annotated PMM in the
genome as well as in vitro biochemical activity and HAD5KD
growth rescue by mannose provide a compelling argument
that HAD5 is a functional PMM of P. falciparum. While residual PMM activity present in HAD5KD parasites may prevent
GPI synthesis from being completely eliminated, it is insufﬁcient to sustain parasite growth. This speaks to an exquisite
sensitivity of malaria parasite cells to disruption in this
pathway, whereby minor perturbations in GPI anchor synthesis nonetheless completely interrupt parasite growth,
highlighting the promise of this pathway as a therapeutic
target.
In addition, we found that HAD5KD parasites have a complete cell cycle arrest, although others have found that
untethering MSP1 from the membrane by removing its GPIanchoring C terminus still allows for minimal parasite
growth (18). We expect that this discrepancy is because of the
role of HAD5 in function of all GPI-anchored parasite proteins, not solely MSP1. These other GPI-APs include related
MSPs, rhoptry-associated membrane antigen, and 6-cysteine
proteins, many of which are refractory to deletion and likely
essential (15, 20, 34, 82). With the incomplete loss of GPI
synthesis, it may be that each one of these GPI-APs, including
MSP1, are only relatively de-anchored, but the modest
reduction in this posttranslational modiﬁcation across multiple cellular proteins works in concert to cause parasite growth
arrest.
We therefore propose that HAD5, as an upstream member
of the GPI biosynthesis, has great potential as an antimalarial
target. We expect that HAD5 inhibition will have broad
downstream effects on parasite biology across several life cycle
stages. That compound D9 has markedly improved potency
against malaria HAD5 compared to orthologous human enzymes provides key proof-of-concept for ongoing development
of speciﬁc HAD5-directed antimalarial therapeutics. While
compound D9 has limited antimalarial efﬁcacy, this is likely
because of its charged phosphonate, expected to have poor
cellular penetration. This liability may be improved through a
variety of medicinal chemistry strategies, including the addition of prodrug moieties to mask this charge, a strategy that
has been highly effective for other phosphonate antimalarials
in development (83–85). Finally, the crystal structure of HAD5
is likely to be valuable to ongoing efforts to develop more
potent and speciﬁc HAD5 inhibitors as antimalarials.
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This study also adds to the growing literature on HAD-like
proteins in P. falciparum. Three related HAD proteins each
independently modulate parasite sensitivity to the isoprenoid
biosynthesis inhibitor FSM, which prompts the question of
whether this effect would be similarly seen with other HAD
proteins (68–70). Alternatively, the nonmevalonate isoprenoid
biosynthesis pathway may be particularly sensitive to cellular
metabolic perturbations. We found that HAD5 serves as an
interesting counterexample. HAD5 knockdown yields no
changes to FSM sensitivity, providing evidence of a HAD
protein and a metabolic perturbation that does not impact the
sensitivity of parasites to inhibition of isoprenoid metabolism.
Finally, we note that HAD5 and the GPI anchor biosynthesis
pathway are expressed throughout the parasite’s life cycle.
Several GPI-APs are expressed in gamete-stage and oocyststage parasites (86, 87), and circumsporozoite protein, the
target of the RTS,S malaria vaccine and the more recent R21
vaccine candidate (25–28), is a GPI-AP expressed on the
surface of sporozoites that facilitates sporozoite development
(29) and targets sporozoites to the liver (88). Furthermore,
sexual-stage parasites harbor additional fates of M1P,
including C-mannosylation (89, 90) and O-fucosylation (91,
92), suggesting that HAD5 will play a critical role in parasite
biology across several life stages. Hence, HAD5 serves an
essential role in parasite metabolism and shows promise as a
speciﬁc therapeutic target. The inhibition of HAD5 not only
has potential to treat intraerythrocytic P. falciparum infection
but also may serve to block transmission.

Experimental procedures
Parasite strains and culturing
Unless otherwise indicated, parasites were maintained at 37
C in 5% O2, 5% CO2, 90% N2 in a 2% suspension of human
RBCs in RPMI medium (Gibco) modiﬁed with the addition of
30 mM NaHCO3, 11 mM glucose, 5 mM Hepes, 1 mM sodium
pyruvate, 110 μM hypoxanthine, 10 μg/ml gentamicin,
(Sigma), and 2.5 g/l AlbuMAX I (Gibco). Deidentiﬁed RBCs
were obtained from the Barnes-Jewish Hospital blood bank, St
Louis Children’s Hospital blood bank, and American Red
Cross Blood Services.
The HAD5 conditional knockdown strain, “HAD5KD,” was
generated by transfecting NF54attB parasites (93) using
methods as described (46, 47). Resultant parasites were
maintained in the presence of aTc (Cayman Chemicals) in
dimethylsulfoxide at 500 nM unless otherwise speciﬁed. Parasites were synchronized with a combination of 5% sorbitol
(Fisher Bioreagents) and 1.5 μM Compound 1 (MedChemExpress) (94, 95).


Plasmodium growth measurement
Parasitemia in daily growth assays was measured via ﬂow
cytometry by incubating 10 μl of parasite culture with 190 μl of
0.4 μg/ml acridine orange (Invitrogen) in PBS for 1 min.
Stained parasites were analyzed on a BD FACS Canto ﬂow
cytometer gating on DNA- and RNA-bound dye signal using
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FITC and PerCP-Cy5.5 ﬁlters, respectively. Fifty thousand
events were recorded for each sample.
Merozoite reinvasion
Merozoite reinvasion was assessed as described (96). Parasites were synchronized, grown in ±aTc, and treated with
10 μM epoxysuccinyl-L-leucylamido(4-guanidino)butane
(E64) (Sigma) for 8 h to stall them in late schizont stages.
E64 was washed out, and cultures were passed through a
1.2 μm ﬁlter to lyse the schizonts. Lysates were incubated
with fresh RBCs for 1 h to allow reinvasion before cultures
were washed again to remove debris. Parasitemia was
assessed 24 h after reinvasion by acridine orange staining and
ﬂow cytometry. Reinvasion efﬁciency was assessed by
normalizing resultant parasitemia to the measured parasitemia prior to lysis.
Light and ﬂuorescent microscopy
Parasite development was monitored by thin smear of
synchronized parasites that were dyed with modiﬁed Giemsa
Stain (Sigma). For ﬂuorescent microscopy, E64-treated
schizont-stage parasites were mechanically lysed by passing
them through a 1.2 μm ﬁlter (96). Lysates were added to
poly-lysine–coated glass slides, ﬁxed in 4% paraformaldehyde, 0.0075%glutaraldehyde in PBS, and permeabilized in 0.1% Triton X-100. Immunoﬂuorescence was
performed using mouse anti-MSP1 monoclonal antibody
(Novus Biologicals) and goat-anti-mouse Alexaﬂuor 488
secondary antibody (Life Technologies). Samples were then
preserved with ProLong Gold antifade reagent with DAPI
(Life Technologies).
All immunoﬂuorescence and bright ﬁeld images were taken
using a Zeiss Axio Observer D1 inverted microscope (Carl
Zeiss Inc), equipped with a Axiocam 503 color camera, at the
Washington University Molecular Microbiology Imaging facility. Images were acquired with a Plan-Apochromat 100×
(NA 1.4) objective using the ZEN 2.3 pro (blue edition) software. Fluorescent signal was quantiﬁed using the ImageStudioLite software from LI-COR.
Transmission electron microscopy
For ultrastructural analyses, highly synchronized infected
RBCs were ﬁxed in 2% paraformaldehyde/2.5% glutaraldehyde
(Polysciences Inc) in 100 mM sodium cacodylate buffer, pH
7.2 for 1 h at room temperature. Samples were washed in
sodium cacodylate buffer and postﬁxed in 1% osmium tetroxide (Polysciences Inc) for 1 h at room temperature. Samples were then rinsed in dH2O, dehydrated in a graded series of
ethanol, and embedded in Eponate 12 resin (Ted Pella Inc).
Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX
transmission electron microscope (JEOL USA Inc) equipped
with an AMT eight megapixel digital camera and AMT Image
Capture Engine V602 software (Advanced Microscopy
Techniques).

Cloning
The coding sequence of HAD5 was cloned from cDNA of
3D7 parasites using primers P1 and P2 (Table S1) and cloned
into the BG1861 vector (97), which introduces an N-terminal
6xHis-tag, by ligation-independent cloning. This coding
sequence was subsequently cut and pasted into a pET28a
vector with NdeI and BamHI-HF (NEB), followed by ligation
with NEB Quick Ligase using manufacturer’s protocols. The
coding sequence did not match published reference sequence
of PF3D7_1017400, as an adenosine-to-guanosine mutation
yielded an Asn-to-Ser substitution at residue 100. To revert
this sequence to the reference sequence, primer P3 (Table S1)
was used in the QuikChange Multisite-directed mutagenesis
kit (Agilent), and the resulting plasmid was transformed into
XL10 Gold ultracompetent Escherichia coli cells. The
HAD5D11A allele was generated from the WT plasmid, again
using the QuikChange multisite-directed mutagenesis kit and
primer P4 (Table S1). Homo sapiens PMM1 and PMM2 coding
sequences were identiﬁed from UniProt, codon optimized for
E. coli, and synthesized by Integrated DNA Technologies
(Table S2). These gene blocks were ampliﬁed and extended
using primers P5 + P6 (PMM1) and P7 + P6 (PMM2) and
PrimeSTAR GXL DNA polymerase (Takara) (Table S1). These
sequences were then cloned into the pET28a plasmid by
Gibson assembly at NdeI and BamHI-HF cut sites, and plasmids were transformed into XL10 Gold ultracompetent E. coli
cells.
E. coli mannose-1-phosphate guanylyl transferase (ManC)
was cloned for use in PMM assays. The coding sequence of
EcManC was identiﬁed from UniProt, and a gene block of the
sequence was ordered from Integrated DNA Technologies
(Table S2). This sequence was cloned by ligation-independent
cloning into a BG1861 vector that has been modiﬁed with a
starting KFS sequence downstream of the 6xHis-tag to
enhance protein expression (98), and the resulting plasmid was
transformed into Stellar Competent Cells (Takara).
Recombinant protein expression and puriﬁcation
To generate recombinant protein for enzyme assays and
crystallography, the pET28a plasmids were transformed into
BL21 Gold (DE3) competent E. coli cells (Agilent). Cells were
grown to absorbance at 600 nm (A600) of 0.6 to 0.8 in Terriﬁc
Broth medium (24 g/l yeast extract, 20 g/l tryptone, 4 ml/l
glycerol, 17 mM KH2PO4, 72 mM K2HPO4) shaking at 37  C
and then induced for approximately 18 h with 1 mM IPTG at
16  C. Cells were collected by centrifugation and resuspended
in lysis buffer containing 25 mM Tris–HCl (pH 7.5), 250 mM
NaCl, 1 mM MgCl2, 10% glycerol, 20 mM imidazole, and
100 μM PMSF and lysed by sonication. Lysate was centrifuged
at 18,000g for 1 h, and the supernatant containing soluble
protein was bound to nickel agarose beads (Gold Biotechnology), washed with buffer containing 25 mM Tris–HCl (pH
7.5), 250 mM NaCl, 1 mM MgCl2, 10% glycerol, and 20 mM
imidazole, and eluted with 10 ml of buffer containing 25 mM
Tris–HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2, 10% glycerol,
and 320 mM imidazole. Eluate was dialyzed overnight at 4  C
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in the presence of 30 units of thrombin protease (Sigma) into
buffer containing 25 mM Tris–HCl (pH 7.5), 250 mM NaCl,
1 mM MgCl2, and 10% glycerol. The dialyzed, thrombincleaved mixture was then run over nickel agarose beads and
benzamidine sepharose beads (GE Healthcare) to remove the
cleaved His-tag and thrombin. The ﬂow through protein was
collected and further puriﬁed by size-exclusion chromatography using a HiLoad 16/60 Superdex-200 column (GE
Healthcare), equilibrated in dialysis buffer. Elution fractions
containing the protein of interest were identiﬁed by UV
absorbance and SDS-PAGE, pooled, and concentrated to
6 mg/ml. Protein solutions were ﬂash frozen in liquid nitrogen
and stored at −80  C (Figs. 1B and S7A).
EcManC for enzyme activity assays was expressed by
cloning the BG1861:ManC vector into BL21(DE3) pLysS
E. coli cells (Life Technologies). Cells were grown in LB broth
to an A600 of 0.7 to 0.8 and induced with 1 mM IPTG for 2 h
at 37  C. Cells were harvested, and protein was puriﬁed as
described for other proteins above. However, as this
construct lacked the thrombin-cleavable site from the
pET28a vector, the elution from nickel beads was directly run
over the size exclusion column, then pooled and concentrated (Fig. S7B).

Inhibition assays of recombinant HAD5
Synthesis of compounds D1 to D11 (Fig. S8A) has been
described previously (73, 74), with the exception of compound
D9, whose synthesis is described, and characterization data are
included, in the attached supporting information. To assess
inhibition of HAD5, compounds D1 to D11 were suspended in
water and added to the PGM assay of HAD5 activity (the
PMM assay was not used, as cross-inhibition was seen with
downstream components of that assay but not with the PGM
assay; Fig. S8D). Five microliters of water volume in the assay
was replaced with 5 μl serial dilutions of analogs, with ﬁnal
concentrations ranging from 0 μM to 1 mM. The rate of
product formation in each condition was used to determine
the IC50 for each inhibitor. In addition to HAD5, these assays
were performed with recombinantly puriﬁed human PMM1
and PMM2. For these inhibition assays, 200 ng of HAD5
(139 nM), PMM1 (133 nM), or PMM2 (65 nM) was used to
start the reaction.
Time-dependent inhibition was assessed by preincubating
HAD5 or PMM1 in 416 μM D9 for time points up to 60 min,
before adding the enzyme + inhibitor mixture to the full reaction mixture, achieving a ﬁnal [D9] of 50 μM.
Parasite growth inhibition assays

HAD5 activity assays
PMM activity of HAD5 was measured using a linked
enzyme scheme (Fig. S1A), modiﬁed from the EnzChek
phosphate release kit (ThermoFisher Scientiﬁc). Two hundred
micromolar of 2-amino-6-mercapto-7-methyl-purine riboside
and 1× EnzChek reaction buffer (50 mM Tris HCl, 1 mM
MgCl2, pH 7.5, containing 100 μM sodium azide) were incubated with 1 U/ml purine nucleoside phosphorylase, 1 U/ml
pyrophosphatase, 125 μM GTP, 52 μg/ml recombinant puriﬁed E. coli ManC, and 1 mM mannose-6-phosphate. 12.5 μM
G-1,6-P was also added to demonstrate its activating properties on HAD5. All reagents were obtained from Sigma-Aldrich.
The reaction was started by adding 50 ng recombinant HAD5
(WT or D11A), which is within the linear range of the assay
(Fig. S1B). Reactions took place in 40 μl, and the production of
nucleotide by purine nucleoside phosphorylase was measured
at 360 nM.
PGM assays (Fig. S1C) were developed by incubating 1 mM
glucose 1-phosphate, 0.75 mM NADP+, 2.5 U/ml glucose-6phosphate dehydrogenase, and 10 μM G-1,6-P in 50 μl reactions containing 25 mM NaCl, 25 mM Tris–HCl, pH 7.5,
and 1 mM MgCl2. All reagents were obtained from SigmaAldrich. Again, 50 ng of HAD5 was added to start the reaction (Fig. S1D), and the production of reduced NADPH was
measured by absorbance at 340 nm.
All reactions took place at room temperature in clear CoStar
96-well half-area plates, and absorbances were measured by a
PerkinElmer multimode Envision plate reader. For MichaelisMenten kinetics of each assay, 2-fold serial dilutions of substrate concentrations (either M6P or glucose 1-phosphate,
respectively) were made, and all other components of the assays were kept constant.
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Dose–response inhibition experiments were performed on
asynchronous parasites. Three experimental replicates were
performed, with technical duplicates, for each experiment.
Both GlcN and ManN inhibition experiments were performed by adding 2-fold dilutions of each compound in water,
from 0 mM to 2 mM, to a 100 μl culture of parasites. One
micromolar of chloroquine was used as a positive control.
Inhibition of cultured parasites by compound D9 was assessed
using 100 μM D9 or equivalent volume of water. The parasite
growth in these experiments was assessed by acridine orange
staining and ﬂow cytometry measurement of parasitemia 72 h
after treatment.
Dose–response of FSM was assessed using concentrations
up to 50 μM FSM in water, and the growth was measured after
72 h treatment on a PerkinElmer multimode Envision plate
reader by Quant-iT PicoGreen dsDNA reagent (ThermoFisher
Scientiﬁc) staining.
Western blotting
To verify tagging and knockdown of protein, cultures of
HAD5KD were grown for 24 h in ±aTc conditions, then RBCs
were lysed with cold PBS + 0.1% saponin. Samples were
centrifuged to pellet parasites and remove excess hemoglobin,
then the parasites were lysed in RIPA (50 mM Tris, pH 7.4;
150 mM NaCl; 0.1% SDS; 1% Triton X-100; 0.5% DOC) plus
HALT-Protease Inhibitor Cocktail, EDTA-free (ThermoFisher
Scientiﬁc). Lysates were centrifuged at high speed to pellet and
remove hemozoin. Cleared lysates were then diluted in SDS
sample buffer (10% SDS, 0.5 M DTT, 2.5 mg/ml bromophenol
blue, 30% 1 M Tris pH 6.8, 50% glycerol) and boiled for 5 min.
Lysates were separated by SDS-PAGE, then transferred to
0.45 μm nitrocellulose membrane (ThermoFisher Scientiﬁc).
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The membranes were blocked in PBS + 3% bovine serum albumin, then probed with primary antibodies: rabbit anti-HA
(Sigma), mouse anti-plasmepsin V (99, 100). Membranes
were washed in PBS + 0.5% Tween 20, then probed with
secondary antibodies goat anti-rabbit IRDye 800CW 1:20,000
(LI-COR) and donkey anti-mouse IRDye 680LT 1:20,000 (LICOR). Membranes were then washed in PBS + 0.1% Tween 20
and imaged on a LI-COR Odyssey platform.
Autoradiography and GPI anchor quantiﬁcation
GPI anchor autoradiography was performed as previously
described (17, 57, 59). Brieﬂy, 33- to 39-h-old parasites that
had been grown in ±aTc conditions were washed and resuspended in glucose-free media (RPMI R1383 + 20 mM
D-fructose, 25 mM Hepes, 21 mM NaHCO3, 0.37 mM hypoxanthine, 11 mM glutathione, 5 g/l Albumax I, and 10 μg/ml
gentamicin). One hundred ﬁfty microcurie of 40 Ci/mmol [3H]
GlcN (American Radiochemicals) was added to each 10 ml
culture and incubated for 3 h. Parasites were saponin lysed,
and glycolipids were extracted with chloroform:methanol:
water (10:10:3), nitrogen evaporation, and n-butanol partitioning (60). The resultant glycolipids were run on TLC
Silica gel 60 F254 plates (Millipore Sigma) using chloroform:methanol:water (10:10:3) as a solvent. The TLC plates
were exposed to autoradiography ﬁlms (MidSci), which were
developed after 1 week of exposure. Films were imaged on a
BIO-RAD ChemiDoc MP imaging system, and the signal was
quantiﬁed by the ImageLab software from Bio-Rad.
TritonX-114 membrane partitioning
Membrane partitioning was adapted from Doering et al.
(64). Brieﬂy, at approximately 40 to 44 h after invasion, synchronized parasite cultures were magnetically puriﬁed (Miltenyi Biotec), and the elution was centrifuged and resuspended
in 1 ml ice-cold Tris-buffered saline (TBS) + 1× HALT protease inhibitor cocktail, EDTA-free (ThermoFisher Scientiﬁc).
Two hundred microliter precondensed Triton X-114 was
added to lyse parasites, and lysates were incubated on ice for
15 min. Lysates were centrifuged to remove debris. Then followed a series of ﬁve extractions with cold TBS + protease
inhibitor and precondensed TritonX-114, followed by warming to 37  C and centrifugation to separate phases. The lysate,
detergent-enriched phase and the soluble phase were analyzed
by SDS-PAGE and Western blotted as described previously
using mouse anti-plasmepsin V 1:20 (99) and rabbit antiHAD1 1:10 (68) or rabbit anti-MSP1 1:1000 MSP1 (101).
Detergent samples were diluted 5-fold in TBS prior to SDSPAGE to avoid TritonX-114 interference with the gel.
Protein crystallography and ligand docking


Crystals of P. falciparum HAD5 were grown at 4 C using
vapor diffusion in hanging drops comprised of 2 μl protein
(6 mg/ml) and 2 μl crystallization buffer (0.1 M Bis–Tris
propane pH 6.5, 0.1 M calcium acetate, 16% (w/v) PEG
8000, and 2% (v/v) benzamidine hydrochloride). Prior to data
collection, crystals were ﬂash frozen in mother liquor

supplemented with 25% glycerol. All diffraction images were
collected at 100K at beamline 19-ID of the Structural Biology
Center at Argonne National Laboratory Advanced Photon
Source. HKL3000 was used to index, integrate, and scale the
datasets (102). Prior to phasing, a homology model of PfHAD5
was created using SWISS-MODEL (103) based on human
alpha PMM 1 (PDB: 6CFR (104), sequence identity 51%).
Molecular replacement was performed using PHASER (105)
and the homology model of PfHAD5 as a search model.
COOT and PHENIX were used for iterative rounds of model
building and reﬁnement (106, 107). Data collection and
reﬁnement statistics are summarized in Table 2. Atomic coordinates and structure factors of PfHAD5 have been deposited in the RCSB Protein Data Bank (PDB: 7MYV).
The PfHAD5 structure was prepared for docking using
AutoDock Tools 1.5.7 (108). The three-dimensional structure
of compound D9 was prepared using Avogadro (109) and was
prepared for docking using AutoDock Tools 1.5.7. Docking
was performed with AutoDock Vina using default search settings (110).

Data availability
Atomic coordinates and structure factors of PfHAD5 have
been deposited in the RCSB Protein Data Bank (PDB: 7MYV).
All other data have been provided in ﬁgures and supporting
information.
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